

Emosis strengthened by a second round of 1 million euros investment.

Few days after initiating its commercial operations, Emosis raises another 1 million Euros from Cap Innov'Est, to fuel growth and innovation.

Strasbourg Area, France, June 26th 2018

Emosis, a medical device company specializing in cytomolecular diagnostics of hemostasis and thrombotic disorders, is proud to announce the closing of a €1M funding round from its historical investor Cap Innov'Est. This is the second capital raise since the incorporation of the company in January 2015. The proceeds will be primarily used to sustain international commercialization of the company's first Emo-test product HIT Confirm® and to deploy internal and external growth strategy – moving next products in line closer to market and undergoing new partnerships to scale-up Emosis business.

Dr. Frédéric Allemand, Emosis CEO, commented: "It is a timely raise while we are starting to sell HIT Confirm®, and have a full range of internal and external value creation opportunities within reach. Cap Innov'Est is a faithful partner to Emosis, that continues to share our vision to grow Emosis into an international company with a leading franchise in hemostasis diagnostics, a dynamic market with promising high growth perspectives."

Jean-François Rax, Head of Investments from Cap Innov'Est, confirmed: "We are very pleased to follow-up on our initial

investment in Emosis. The company's team has been highly capital efficient in bringing its first product HIT Confirm to the market since the initial fund raising, and the company faces attractive opportunities to create additional value."

Anh Nguyen, PhD, MBA, Chairman of the Supervisory Board, added: "This second round of investment with Cap Innov'Est is the confirmation of the amazing work done so far and will support Emosis constant growth in order to deploy its products."

ABOUT EMOSIS

Emosis is an innovative medical device company specializing in cytomolecular diagnostics of hemostasis and thrombosis disorders. The company is dedicated to the clinically-centered development, marketing and commercialization of first-in-class, on-demand and user-friendly assays, Emo-tests, to be routinely performed on the rapidly growing new generation of low cost and operator friendly flow cytometers. Emo-tests aim to inform physician medical decision with respect to bleeding or clotting events (or risk of) in a broad range of clinical settings, encompassing cardiovascular and neurovascular diseases, cancer, pregnancy, and pharmacological and non-pharmacological therapy management.

About Cap Innov' Est

Cap Innov'Est is a 36M€ tri-regional fund dedicated to investments in young innovative start-ups. Cap Innov'Est was launched in July 2014 and has already invested in 13 start-ups. Cap Innov'Est is supported by Fonds National d'Amorçage, the 3 Regions Alsace, Bourgogne and Franche-Comté, SAFIDI, caisses d'épargne d'Alsace et Bourgogne/Franche-Comté, BNP Paribas et CIFIC.

